| First choice | VKAs remain the standard of care in patients with AF undergoing cardioversion |
| The available data suggest that the NOACs are safe and effective alternatives, with practical advantages such as shortening the time to cardioversion | |
| Comment | Post hoc analyses suggest no apparent differences in safety and efficacy between apixaban, dabigatran, and rivaroxaban |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.